

effectiveness for implantable MIGS devices. By bringing together relevant stakeholders, we hope to facilitate the improvement of regulatory science in this rapidly evolving product area.

FDA and AGS recognize the unique opportunity this workshop provides for all stakeholders of the ophthalmic device community to work together to improve trial design for the assessment of new MIGS devices, and, thereby, strengthen contributions to improved patient care and the protection of the public health.

## II. Topics for Discussion at the Public Workshop

Topics to be discussed at the public workshop include, but are not limited to:

- Definition of MIGS and overview of these procedures;
- defining the patient population for implantable MIGS devices;
- determining effectiveness endpoints for implantable MIGS devices; and
- determining the appropriate safety parameters for implantable MIGS devices.

These topics will be presented by experts in the associated area, and will be discussed by panelists with extensive experience conducting glaucoma clinical research.

Dated: January 28, 2014.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2014-02146 Filed 1-31-14; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2014-N-0124]

#### Science Board to the Food and Drug Administration: Request for Nominations

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations to serve on the Science Board to FDA (Science Board).

FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

**DATES:** Nominations received on or before March 5, 2014, will be given first

consideration for membership on the Science Board. Nominations received after March 5, 2014 will be considered for nomination to the Board should nominees still be needed.

**ADDRESSES:** You may submit your information by logging into the FDA advisory Committee Membership Nomination Portal: <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm> or by mail to Advisory Committee Oversight and Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002. Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA's Web site at <http://www.fda.gov/AdvisoryCommittees/default.htm>.

**FOR FURTHER INFORMATION CONTACT:** Martha Monser, Office of the Chief Scientist, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 4286, Silver Spring, MD 20993-0002, 301-796-4627, email: [martha.monser@fda.hhs.gov](mailto:martha.monser@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** FDA is requesting nominations to the Science Board. The Science Board will meet approximately three times a year. All meetings will be announced in the **Federal Register** at least 15 days prior to each public meeting.

### I. General Function of the Committee

The Science Board shall provide advice primarily to the Commissioner and other appropriate officials on specific complex scientific and technical issues important to FDA and its mission, including emerging issues within the scientific community. Additionally, the Science Board will provide advice that supports the Agency in keeping pace with technical and scientific developments, including in regulatory science; and input into the Agency's research agenda; and on upgrading its scientific and research facilities and training opportunities. It will also provide, where requested, expert review of Agency sponsored intramural and extramural scientific research programs.

### II. Desired Expertise

FDA is specifically seeing persons knowledgeable in the fields of food science, safety, and nutrition; chemistry; pharmacology; translational and clinical medicine and research; toxicology; biostatistics; medical devices; imaging; robotics; cell and tissue based products; regenerative medicine; public health and epidemiology; international health and regulation; product safety; product manufacturing sciences and quality; and

other scientific areas relevant to FDA regulated products such as systems biology, informatics, nanotechnology, combination products and relevant areas of behavioral and social science. Members shall be chosen from academia and industry. The Science Board may also include technically qualified federal members.

### III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership on the Science Board. Self-nominations are also accepted. Nominations must include a current, complete resume or curriculum vitae for each nominee, including a current business address and/or home address, telephone number, and email address if available. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: January 29, 2014.

**Jill Hartzler Warner,**

*Acting Associate Commissioner for Special Medical Programs.*

[FR Doc. 2014-02155 Filed 1-31-14; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Amended Notice of Meeting

Notice is hereby given of changes in the meeting of the National Institute on Drug Abuse Special Emphasis Panel, February 6, 2014, 10:00 a.m. to February 6, 2014, 12:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, which was published in the **Federal Register** on January 10, 2014, 79, 8 FRN2014-00301.

The date of the meeting is changed to February 11, 2014. The meeting is closed to the public.

Dated: January 28, 2014.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-02103 Filed 1-31-14; 8:45 am]

**BILLING CODE 4140-01-P**